Drugs / natural killer T cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02562963 | Nov 2015 → May 2023 | colorectal cancer, gastric cancer, hepatocellular carcinoma, non-small cell lung carcinoma | Minghui Zhang | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | natural killer T cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02562963 ↗ |
| Known as | NKT | “Natural killer T (NKT) cells are a unique subset of lymphocytes that present a mixed T-NK phenotype.” NCT02562963 ↗ |
| Modality | Cell therapy | “The eligible patients are infused with two doses of (4±0.5)x10\^9 NKT cells in one course of treatment.” NCT02562963 ↗ |